Neuro-oncology: The long and winding road - Gene therapy for glioma

Nature Reviews Neurology

Volumn 9, Issue 11, 2013, Pages 609-610

  Castro, Maria G ^a   Lowenstein, Pedro R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; HERPESVIRUS VECTOR; RETROVIRUS VECTOR; SITIMAGENE CERADENOVEC; THYMIDINE KINASE;

ARTICLE; CANCER GENE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFICACY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOSTIMULATION; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; FEMALE; GANCICLOVIR; GENETIC THERAPY; GLIOMA; HUMANS; MALE; THYMIDINE KINASE;

EID: 84887244991     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.198     Document Type: Article

References (9)

1. Grossman, S. A. et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 16, 2443-2449 (2010).
2. Rainov, N. G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11, 2389-2401 (2000).
3. Westphal, M. et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT : A randomised, open-label, phase 3 trial. Lancet Oncol. 14, 823-833 (2013).
4. Sandmair, A. M. et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retrov iruses or adenoviruses. Hum. Gene Ther. 11, 2197-2205 (2000).
5. Immonen, A. et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol. Ther. 10, 967-972 (2004).
6. Ark Therapeutics Ltd withdraws its marketing authorisation application for Cerepro (sitimagene ceradenovec). European Medicines Agency [online], http://www.ema.europa.eu/ ema/index.jspcurl=pages/medicines/human/medicines/ 001103/wapp/Initial-authorisation/human-wapp-000083.jsp&mid= WC0b01ac058001d128 (2011).
7. Meade, T. Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. Handb. Exp. Pharmacol. 210, 565-605 (2012).
8. Wollmann, G., Odzuman, K. & van den Pol, A. N. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J. 18, 69-81 (2012).
9. Curtin, J. F. et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 6, e10 (2009).